© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
August 11, 2022
Nancy Lurker, CEO of EyePoint Pharmaceuticals, shares the 12-month safety data from the DAVIO trial, investigating EYP-1901 for the treatment of wet age-related macular degeneration (AMD) and nonproliferative diabetic retinopathy.
August 09, 2022
Victor Gonzalez, MD, shares updates from the Phase 4 Paladin study regarding the safety and efficacy of fluocinolone in diabetic macular edema.
August 02, 2022
Claire Gelfman, PhD, Chief Scientific Officer of Foundation Fighting Blindness, supplies a brief overview of the foundation's aims and updates on retinal disease research.
July 26, 2022
At ASRS 2022, John Kitchens, MD, presented, “Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab."
July 23, 2022
Kerrie Brady, CEO of OcuTerra Therapeutics, shares an update on their eye drop-based integrin inhibitor, which is intended to be a novel therapy for diabetic retinopathy.
July 20, 2022
At ASRS 2022, Sunir Garg, MD, FACS, discussed his talk entitled, “Impact of Delay in Repair of Rhegmatogenous Retinal Detachment: Real-World Outcomes from the IRIS Registry.”
July 19, 2022
At ASRS 2022, Sally Ong, MD, presented a talk entitled, “Vitrectomy vs Vitrectomy With Scleral Buckling in the Treatment of Giant Retinal Tear Related Retinal Detachments: International Multicenter Study.” Here she shares the biggest takeaways.
July 18, 2022
The American Society of Retina Specialists held its 40th Annual Meeting in New York, New York, from July 13-16, 2022. While data was presented for all topics in retina, new revelations in age-related macular degeneration, diabetic retinopathy, and diabetic macular edema dominated the conversation.
July 16, 2022
J. Fernando Arevalo, MD, PhD, investigated the anatomic and functional outcomes of pars plana vitrectomy, scleral buckle, or a combination of the two, and suggested that the combination approach may need further consideration.
Rahul Khurana, MD, discusses his 2022 ASRS talk, “Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor in Patients With DME Who Respond Suboptimally to Anti-VEGF Treatment (Month 6 Results of Part A of the KALAHARI Study),” which he presented in New York City, New York.